Tag: Hormone Replacement Therapy
Hormone Therapy Not Associated With Glioma Risk in Women
Similar findings with no significant association seen when accounting for hormone therapy status and duration of use
Rural Women May Have Higher Burden of Menopause Symptoms
Burden greater for psychological and somatic menopause symptoms, but not vasomotor symptoms
Tibolone, Oral Estrogen-Progestin Therapy Linked to Risk for Heart Disease
Risk for ischemic heart disease elevated for initiators of tibolone or oral estrogen-progestin therapy
No Long-Term Cognitive Effects Seen for Menopausal Hormone Therapy
No long-term cognitive effects of mHT were seen in the KEEPS Continuation study, about 10 years after completion of randomized treatment
ACG: Hormone Therapy Tied to Higher Risk for New Irritable Bowel Syndrome
Hormone replacement therapy also tied to elevated gastrointestinal symptoms and diagnostic testing
1999 to 2020 Saw Decline in Menopausal Hormone Therapy Use
Decreases seen for women aged younger than 52 years, 52 to <65 years, and 65 years and older, and for Hispanic, non-Hispanic Black, non-Hispanic White women
2007 to 2023 Saw Decline in Menopausal Hormone Therapy Usage Rates
Rates declined and remained low for women aged 45 to 49, 50 to 54, and 55 to 59 years
Hormone Therapy Tied to Less Biological Aging in Postmenopausal Women
Biological aging discrepancy mediated the association between HT and decreased mortality
Long-Term Study of Postmenopausal Women Does Not Support Many Preventive Therapies
Hormone therapy no aid for cardiovascular disease prevention, and calcium/vitamin D supplementation no aid for universal fracture prevention
Menopausal Hormone Therapy Use Beyond 65 Years Beneficial
Hormone therapy use linked to risk reductions in mortality
